Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (5706)	10/1/1998 2:27:00 PM
From: Biomaven	Respond to of 9719

If anyone is in the mood for some wild speculation, they could take a look at Intercardia (ITRC). It's basically a gamble on how the ongoing Bextra (bucindolol) trial for congestive heart failure comes out. The drug is all theirs now, and it's in late Phase III. Concerns are there is now some competition, the trial hasn't been stopped yet which people had been hoping for, and the IPIC connection. Market cap of less than $30m, cash of around $20m with some more to come from Astra-Merck because of the partnership termination, which Astra Merck was resisting. Might be just the sort of thing that CHIR was looking for - a substantial, late-phase cardiac product. I picked up a little this morning at 4. If the Bextra trial is a bust it'll go to less than cash, but if it succeeds it should go back into the 20's or more. Peter